COLUMBIA, MD and TORONTO -- (Marketwire) -- 02/25/13 -- Medifocus Inc. (OTCQX: MDFZF) (TSX VENTURE: MFS) is pleased to announce it has obtained a newly allowed patent to add to its extensive intellectual property portfolio of over 100 issued and/or pending US and foreign patents covering its two platform technologies for the treatment of breast, rectal, ovarian cancer and prostate diseases.
This patent was granted on February 12, 2013 by the United States Patent and Trademark Office (USPTO) to John Mon, Chief Operating Officer of Medifocus, and Dr. Alan Fenn, and has been assigned to Medifocus. The title of the patent is "Drug Delivery" and is a method and apparatus for the treatment of tissue adjacent to a bodily conduit by "thermocompression" and drug-encapsulated within a heat-sensitive carrier, such as a liposome, within a region of the tissue to be treated.
Medifocus' Prolieve® Thermodilatation System is currently used for the treatment of enlarged prostate, or Benign Prostatic Hyperplasia ("BPH"). This new patent allows the Prolieve® Thermodilatation System to be used in conjunction with cancer drugs encapsulated within heat-sensitive carriers to treat prostate cancer, as well as other cancers.
Augustine Cheung, Chief Executive Officer of Medifocus, Inc., commented, "This patent expands the potential use of the Prolieve® Thermodilatation System beyond treating BPH, from a commercial perspective. Now, the opportunity, subject to regulatory approval, to utilize our existing Prolieve® technology as a means of drug delivery for prostate cancer significantly expands the technology's market potential."
About Medifocus, Inc.
Medifocus develops and commercializes minimally invasive, unique focused heat treatment systems used in treatment of cancerous and benign tumors, and enlarged prostate,or Benign Prostatic Hyperplasia ("BPH").
The Company owns two technology platforms with comprehensive US and international patent protection: The "Endo-thermotherapy Platform" and the "Adaptive Phased Array Microwave Focusing Platform". Based on these platform technologies, the Company has developed two advanced therapeutic products: the Prolieve® system for the treatment of BPH, and the Adaptive Phased Array (APA)-1000 system for treatment of breast cancer.
The U.S. FDA-approved Prolieve® System (www.prolieve.com) is a medical device based on endo-thermotherapy that both heats the prostate and dilates the prostatic urethra. The heating plus dilatation treatment offered by the Prolieve® System is the only minimally invasive treatment which offers both immediate and long term relief of symptoms due to enlarged prostate (BPH) in men. The clinical indication received for Prolieve from the FDA is an "alternative to drug therapy." With this indication, the Prolieve® System is a revenue generating device based product which can have the potential of catering to the $8 billion non-surgical prescription drug therapy market for treatment of BPH.
Most Popular Stories
- Saab Gets Back into the Game; U.S. Auto Sales Soar
- Dell Offers Undisclosed Number of Employee Buyouts
- Authorities Close to Deal with JPMorgan Chase over Madoff Response
- Apple Activates Customer-Tracking iBeacon
- 2013 Tech Gift Guide: iPad Mini Still Hot; Chromecast a Great Low-Cost Option
- A Biography of Jonathan Ive, Apple's Creative Chief
- It's No Yolk: Food-tech Startups Take Aim at Replacing Eggs